创胜集团-B：截至2025年12月31日止年度的全年业绩公告

20251231 2025123120241231 •2024123111.3202512317.4CDMO•2024123123.58.32025123115.220251231•2024123120.28.12025123112.1 •20241231192.151.320251231140.8 •2024123170.511.52025123159.0 •20241231294.39620251231198.3 •2024123111.3202512317.4CDMO •2024123123.58.32025123115.220251231 •20241231178.141.920251231136.2 •2024123160.55.12025123155.4 •20241231270.480.420251231190.0 Claudin18.2osemitamab (TST001)Claudin18.26ASCO12ESMO AsiaI/IITranStar102GosemitamabCAPOX26CLDN18.2≥40% ≥2+PD-L1 CPS25.816.668%18.0III(TranStar301)(FDA)osemitamab (TST001) osemitamab (TST001)20262026TranStar301 III osemitamab (TST001)TST003TST105 TST013 TST198ozekibart4(AACR)TST105FGFR2bMMAEozekibartInhibrxII2026FDA(BLA)ozekibart TST801BAFFAPRILTST808APRILFDA12(BMD)blosozumab EirGenixTWSE6589 59.34 OsemitamabTST001ADCCClaudin18.2 •20253Claudin18.2 •20256osemitamab(TST001)CAPOX(TranStar102)IIG#40322025ASCO2614G11 IHC LDTCLDN18.240%2+3+PDL1(mOS)21.7(mPFS)16.6(cORR)68%(mDoR)18.0 •202512ESMO Asiaosemitamab (TST001)CAPOX(G/GEJ)I/IITranStar102GCLDN18.2PD-L1PD-L1 CPS<1≥1CLDN18.2(≥40%≥2+)CLDN18.2<(40%≥2+)osemitamabPD-L1osemitamab Osemitamab (TST001)(CDx) •CDxClaudin18.2(CDx)osemitamab (TST001)Claudin18.2TranStar301III TST106CLDN18.2ADC •TST106(ADC)CLDN18.2CLDN18.2IND TST198RDCClaudin18.2 •TST198RDCClaudin18.2RDCRDC TST786PD1-VEGFGREMLIN-1 •TST786PD1VEGFGREMLIN-1GREMLIN-1PD1-VEGFPFSOSPFSOS •2025 TST013LIV-1ADC •TST013LIV-1ADCLIV-1ADCTOPO-IPKADCINDADCTST013 •PDXADCIND TST105ADC •TST105FGFR2b(ADC)FGFR2bADC20254AACRTST105IMMAEADCAACRTST105FGFR2b TST801 •TST801BAFFTACIBAFFAPRILTACIBBAFFAPRIL(SLE)(LN)IgA(IgAN)(gMG)TST801BINDBAFFTST801TST801BDNA (dsDNA)A (IgA)M(IgM)G (IgG) •PK/PDIND TST808APRILB •TST808APRILBTST808BTST808IgANIND •PK/PD TST008MASP-2BAFF •TST008MASP-2BAFFTST008BIgANSLE LN •TranStar102TranStar101osemitamab(TST001)BMS •Claudin18.2CDxosemitamab(TST001)TranStar301III •osemitamab(TST001) • •20251229TWSE6589(HiCB) •siRNAsiRNACDMO •ExcelPro CHOCHOExcelPro CHO CMCCDMO •CDMO • •ADCRDCXDC CDMO •siRNA • • osemitamab (TST001)Claudin18.2Osemitamab (TST001)FDAMFDSIIIosemitamab (TST001)Claudin18.2(G/GEJ)Claudin18.2 osemitamab (TST001)CMC HiCB™CMCCDMO blosozumab (TST002) PD-L1=1TGFβ=βMASP-2=2IND=FIC=HPV=NSCLC=SLE=LN=TMA=IgA=AMono=Combo=Chemo=DR5=5 (1) (2) TST001TST002TST004TST808TST106TST198 TST003TST786TST801TST0082025 osemitamab (TST001)TST003TST013 •Osemitamab (TST001)Claudin18.2III(TranStar301)osemitamab (TST001)Claudin18.2FDA(MFDS)Claudin18.2 •TST106(ADC)CLDN18.2CLDN18.2 •TST198RDCClaudin18.2 •TST003GREMLIN-1GREM1CRCCRPC•TST786PD1-VEGFGREMLIN-1•TST013LIV-1ADC•TST105FGFR2bADC TST003osemitamab (TST001)Claudin18.2 Osemitamab (TST001)ADCCClaudin18.2 Osemitamab (TST001)Claudin18.2ADCCClaudin18.2(PDAC)osemitamab (TST001)+Claudin18.2PDAC Claudin18.2Claudin18.2III38%Osemitamab(TST001)Claudin18.2ADCCADCCClaudin18.2osemitamab (TST001)~55%Claudin18.2osemitamab (TST001) 2025osemitamab (TST001) •20253Claudin18.2 •20256osemitamab (TST001)CAPOX(TranStar102)IIG#40322025ASCO2614G11 IHC LDTCLDN18.240%2+3+PDL1(mOS)21.7(mPFS)16.6(cORR)68%(mDoR)16.5 •202512ESMOAsiaosemitamab(TST001)CAPOX(G/GEJ)I/IITranStar102GCLDN18.2PD-L1PD-L1CPS<1≥1CLDN18.2CLDN18.2osemitamab(TST001)PD-L1osemitamab (TST001) Osemitamab (TST001)CDx •CDxClaudin18.2(CDx)osemitamab (TST001)Claudin18.2TranStar301III TST003GREMLIN-1 TST003GREMLIN-1FIHTST003PK CLDN18.2ADC •TST106(ADC)CLDN18.2CLDN18.2IND TST198RDCClaudin18.2 •TST198RDCClaudin18.2RDCRDC TST786PD1-VEGFGREMLIN-1 TST786PD1-VEGFGREMLIN-1GREMLIN-1PD1-VEGFPFSOSPFSOS •2025 TST013LIV-1ADC TST013LIV-1ADCLIV-1ADCTOPO-IPKADCADCTST013 •PDXADC TST105ADC TST105FGFR2b(ADC)FGFR2bADC •20254A A C RT S T105TST105IMMAEADCAACRTST105FGFR2b blosozumab (TST002)TST004TST008 TST801TST808 blosozumab (TST002)IITST801IgASLE1844 Blosozumab (TST002) Blosozumab(TST002)blosozumabIIblosozumab(BMD)12blosozumabBMD17.7%BMD6.2%32blosozumab( T S T002)85BMD1,200mgblosozumab (TST002)85(D85)BMD3.52%6.20%BMD1.30%2.24%PK/PDIICTP TST004IgANMASP-2 TST0042(MASP-2)IgANMASP-2I TST801 TST801BAFFTACIBAFFAPRILTACIBBAFFAPRILSLELN IgAN gMG pSSTST801BINDBAFFTST801TST801BdsDNAIgA IgMIgG •PK/PDIND TST808APRILB TST808APRILBTST808BTST808IgANIND •PK/PD MASP-2BAFF TST008MASP-2BAFFTST008BIgANSLELN 18A.08(3) ADC BMSosemitamab (TST001)blosozumab(TST002)TST004ADC Osemitamab (TST001) osemitamab (TST001)Claudin18.2PDAC 2 0 2 2( B M S )osemitamab (TST001)®PD-1Claudin18.2BMS osemitamab(TST001)Claudin18.2Claudin18.2osemitamab (TST001)Claudin18.2osemitamab (TST001)III(TranStar301) Claudin18.2CDxIII(TranStar301) Blosozumab (TST002) 2 0 1 9L Y - 2 5 4 1 5 4 6( b l o s o z u m a b )L Y - 3 1 0 8 6 5 3LY-2950913 blosozumab (TST002)GMPINDIIINDIII blosozumab (TST002)FDA(BMD)blosozumab TST004 2020GMPGLPGLP F D AI N DTST004 osemitamab (TST001)TST003TST005 ADCClaudin18.2 •20251229TWSE6589(HiCB) •ExcelPro CHOCHOExcelPro CHO •siRNAsiRNACDMO CMCCDMO 20251229EirGenixTWSE 6589EirGenix(HiCB)EirGenixHiCBCDMOH